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214Mesenchymal Stromal Cells Fail to Prevent Acute
Graft-versus-Host Disease and Graft Rejection after
Dog Leukocyte Antigen-Haploidentical Bone Marrow
Transplantation
Marco Mielcarek,1,2 Rainer Storb,1,2 George E. Georges,1,2 Ludmila Golubev,1 Alla Nikitine,1
Billanna Hwang,1 Richard A. Nash,1,2 Beverly Torok-Storb1Mesenchymal stromal cells (MSCs) have been shown to have immunosuppressive effects in vitro. To test
the hypothesis that these effects can be harnessed to prevent graft-versus-host disease (GVHD) and graft
rejection after hematopoietic cell transplantation (HCT), we administered a combination of 3 different
immortalized marrow-derived MSC lines (15-30 106 MSCs/kg/day, 2-5 times/week) or third-party primary
MSC (1.0  106 MSCs/kg/day, 3 times/week) to canine recipients (n 5 15) of dog leukocyte antigen–
haploidentical marrow grafts prepared with 9.2 Gy of total body irradiation. Additional pharmacological
immunosuppression was not given after HCT. Before their in vivo use, the MSC products were shown to
suppress alloantigen-induced T cell proliferation in a dose-dependent, major histocompatibility complex–
unrestricted, and cell contact–independent fashion in vitro. Among 14 evaluable dogs, 7 (50%) rejected their
grafts and 7 engrafted, with ensuing rapidly fatal acute GVHD (50%). These observations were not statisti-
cally different from outcomes obtained with historical controls (n 5 11) not given MSC infusions (P 5 .69).
Thus, survival curves for MSC-treated dogs and controls were virtually superimposable (median survival, 18
vs 15 days, respectively). Finally, outcomes of dogs given primary MSCs (n5 3) did not appear to be different
from those given clonal MSCs (n5 12). In conclusion, our data fail to demonstrate MSC-mediated protection
against GVHD and allograft rejection in this model.
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Mesenchymal stromal cells (MSCs) suppress prolif-
eration of alloantigen-activated lymphocytes in vitro
in a dose-dependent, cell contact–independent, and
major histocompatibility complex (MHC)-unrestricted
fashion [1-4]. Motivated by the immunosuppressive
properties observed in vitro, MSCs derived from bone
marrow have been evaluated in animal models and in
human patients for treatment and prevention of graft-
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6/j.bbmt.2010.08.015[4-12]. Thus far, most of the evidence documenting
the in vivo immunosuppressive effects of MSC is
based on case reports, small case series, and phase II
studies [13]. Although results have not been over-
whelmingly positive, no acute or long-term adverse
events after MHC infusion, including ectopic tissue
formation, have been reported [14-18].
One obstacle that may limit the effectiveness of
MSCs in vivo is the relatively low numbers of MSCs
that can be generated for clinical applications. In
a recent phase II study of MSCs for treatment of
steroid-resistant, severe acute GVHD, 55 patients
were treated with allogeneic MSCs at a median dose
of 1.4 106 cells (range, 0.4-9 106 cells) per infusion
[17]. Some 89%of patients in this study received a total
of only 1 or 2MSC infusions. Even though the survival
of patients who responded to MSCs in this study
seemed higher (52% at 2 years) than described previ-
ously for patients with similarly severe acute GVHD,
randomized controlled trials unequivocally proving
the usefulness of MSCs for GVHD prevention or
treatment have yet to be published. One recently
Figure 1. Clustering analysis of genes expressed by DS1-3. Three sep-
arate mRNA preparations were analyzed for each DS line. First, genes
on the canine mRNA arrays (Affymetrix) with raw expression levels
.100 were selected. Second, a group of 130 genes with functional
annotations allowing them to be classified as ‘‘extracellular’’ by Gene
Ontology were chosen and were found to include secreted factors,
Biol Blood Marrow Transplant 17:214-225, 2011 215MSCs and GVHDcompleted phase III study of MSCs for treatment of
steroid-refractory acute GVHD has thus far been
presented only in abstract form and showed no benefit
of this intervention with respect to the prospectively
defined primary endpoint of a durable complete
response for $28 days [19]. A subgroup analysis,
however, suggested a possible therapeutic benefit for
patients with liver and gut involvement.
Reports of the effectiveness of MSC infusion in
treating or preventing GVHD have been inconsistent.
We hypothesized that these inconsistencies could be
attributed to several variables, including (1) subopti-
mal numbers of MSCs infused, (2) interdonor varia-
tions in the quality of the marrow harvest, or (3)
varying ratios of MSC subpopulations, leading to
functional differences in bulk cultures. To address
this concern, we used immortalized clonal populations
of canine MSCs to provide a consistent product for
infusion. First, we demonstrated that their in vitro
immunosuppressive potential was comparable to that
of primary MSCs. Next, we tested the canine MSCs’
ability to prevent GVHD and allograft rejection in
a canine dog leukocyte antigen (DLA)-haploidentical
hematopoietic cell transplantation (HCT) model.
Our results indicate that even though clonal MSC
could be produced with high efficiency and were
infused frequently and in high numbers, they failed
to either mitigate or prevent GVHD, or to decrease
the likelihood of rejection.cell surface receptors, and extracellular matrix proteins. The clustering
analysis by the Agilent GeneSpring GX7.3.1 program was based on aver-
age linkage, using the Pearson correlation. DS2 and DS3 differ from DS1
and from each other.MATERIALS AND METHODS
Immortalized Clonal Populations of Bone
Marrow–Derived MSCs
Clonal MSC lines were generated from marrow
derived from 1 donor dog according to procedures
described previously for human MSC lines [20]. In
brief, canine marrow-derived mononuclear cells
were depleted of hematopoietic lineage cells by im-
mune absorption after incubation with anti-CD45
antibodies. The remaining cells were cultured until
confluent and then immortalized with a retrovirus
containing the human papilloma virus E6/E7 genes.
Infected cells were plated at low concentrations, and
growing clones were isolated with cloning rings.
Twenty cloned dog MSC lines, designated DS
1-20, were established. Five DS lines were subse-
quently analyzed in more detail for their ability to
suppress the allogeneic mixed leukocyte culture
(MLC) in vitro. DS1-3, the 3 lines with the strongest
suppressive activity in vitro yet the greatest pheno-
typic differences between one another, were chosen
for further in vivo experiments. The differences in
mRNA profile, immunephenotype and cytokine phe-
notype among DS1-3 are shown in Figure 1, and
Tables 1 and 2.Transcriptome Comparison of DS Lines
MSC lines DS1-3 were grown to semiconfluency,
and RNA was extracted [21]. Using canine mRNA ar-
rays (Affymetrix, Santa Clara, CA), 3 separate mRNA
preparations were processed for each line. Only those
genes with absolute expression values .100 and
adequate annotation to be classified as ‘‘extracellular,’’
‘‘chemokines/growth factors,’’ or ‘‘receptors’’ by Gene
Ontology (GO slims) were considered for further anal-
ysis. The clustering analysis by the Agilent
GeneSpring GX7.3.1 program was based on average
linkage, using the Pearson correlation [21].
Primary MSC Cultures (Long-Term Stromal
Cultures)
Ex vivo culture conditions for primary canine
MSCs were adapted from methods described by Le
Blanc et al. [2] and Gartner and Kaplan [22]. In brief,
buffy coat cells from marrow aspirates were plated in
T-75 flasks (Costar, Cambridge, MA) at 1-2  106/
mL. Adherent cells were grown in long-term marrow
culture (LTC) medium containing Iscove’s modified
Dulbecco’s medium, 12.5% horse serum, 12.5% fetal
Table 1. Phenotypic Characterization of Immortalized Dog Marrow Stromal Cell Lines (DS1-3) and Randomly Selected Primary
Marrow Stromal Cultures (LTCs 1-5)
Marker Detection Method
MSC Type Tested
DS1 DS2 DS3 LTC1 LTC2 LTC3 LTC4 LTC5
MHC class II FC - - - ND ND ND ND ND
CD10 RT-PCR + + + + + ++ + +
CD13 RT-PCR - - - ++ ++ +++ - +++
CD14 FC - - - ND ND ND ND ND
CD29 RT-PCR + +++ + ++ +++ +++ ++ ++
CD34 FC - - - ND ND ND ND ND
CD45 FC/ RT-PCR - - - +++ ++ - - +
CD73 RT-PCR ++ +++ +++ ++ ++ ++ + ++
CD90 FC/ RT-PCR +++ +++ +++ ++ ++ ++ - -
CD105 RT-PCR ++ + ++ +++ +++ +++ - -
CD106 RT-PCR + - - + - ++ - -
ND indicates not done.
Expression levels of informative stromal cell- and lineage-specific markers bymarrow-derived stromal cell lines (DS1-3) and 5 randomly selected primary
marrow stromal cultures (LTC 1-5) were assessed by semiquantitative RT-PCR and flow cytometry (FC) as described in Materials and Methods. Expres-
sion levels of markers of interest were estimated in relation to that of the housekeeping gene, G3PDH, and isotype-matched control antibodies for RT-
PCR and FC, respectively. Expression levels: (+++), strong; (++) intermediate; (+) weak; (-) absent.
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vate (1 mmol/L), penicillin (100 U/mL), streptomycin
sulfate (100 pg/mL), hydrocortisone sodium succinate
(1026 mol/L), and P-mercaptoethanol (1024 mol/L)
and fed weekly by demi-depletion. Stromal layers
were maintained at 37C in an atmosphere of 5%
CO2. After reaching confluency, the adherent layers
were trypsinized once and grown to confluency again
in a T-225 flask to deplete hematopoietic cells before
harvest and infusion. Experiments were performed
with 3-week-old LTC after cells were confluent.Phenotypic Characterization of Stromal Cell
Cultures
Based on the availability of canine cell–specific
monoclonal antibodies, expression levels of informative
stromal and cell lineage–specific markers were asses-
sed by flow cytometry or semiquantitative reverse-
transcriptase polymerase chain reaction (RT-PCR).
For RT-PCR, mRNA was extracted from stromal cell
cultures and transcribed into cDNA using the mMACS
One-Step cDNA Kit (Miltenyi Biotec, Auburn, CA).
PCR reactions were performed using 1.1 PCR
Master Mix plates (Thermo Scientific, Hudson, NH)Table 2. Constitutive Production of Selected Cytokines by Immor
Marrow Stromal Culture (LTCs)
GM-CSF IL-4
DS-1 ND 47.6
DS-2 ND 55.6
DS-3 ND 47.6 1
LTC ND 11.0
Culture medium 16.8 17.1
ND indicates not detectable.
Concentrations of cytokines in 5-day CM from immortalized canine marrow str
determined using the Lincoplex system (Millipore, Billerica, MA). Concentratio
(bottom row) served as a control.containing Thermoprime Plus DNA Polymerase, 1.5
mM MgCl2, and 75 mM Tris-HCl. Then 100 ng of
cDNA template and 2.5 mM of primers (Supplemental
Table 1) were added to each reaction. cDNAwas ampli-
fied over 40 cycles at 94C for 30 seconds, annealing at
58-62C for 45-60 seconds, and extension at 72C for
1minute.Amplifiedproductswere separatedon2%aga-
rose gels and visualized by ethidium bromide fluores-
cence for gene expression. Canine G3PDH was used
as a control for input cDNA and was equivalent in all
samples. Expression levels of markers determined by
flow cytometry (Supplemental Table 1) were compared
with those of isotype-matched control antibodies.Canine Mixed Lymphocyte Cultures and
Mitogen Stimulation
For this, 105 responder peripheral blood mononu-
clear cells (PBMCs) were cultured with 105 irradiated
(24 Gy), allogeneic, DLA-mismatched stimulator
PBMCs at a concentration of 106/mL for 6 days
according to established methods [23]. In some exper-
iments, 105 PBMCswere stimulated with concanavalin
A (conA) at a concentration of 20 mg/mL for 72 hours.
Defined numbers (3-50  103) of irradiated (24 Gy)talized Dog Marrow Stromal Cell Lines (DS1-3) and a Primary
IL-6 IL-8 IL-10 MCP-1
95.7 7857 11.8 787.7
72.2 6002 10.4 2168
16.3 ND 11.5 27.4
87.5 ND 10.3 311.6
ND 166.1 5.0 20.2
omal cell lines DS1-3 and primary marrow stromal cultures (LTCs) were
ns are given in pg/mL. Culture medium incubated without stromal cells
Biol Blood Marrow Transplant 17:214-225, 2011 217MSCs and GVHDclonal MSCs or primary marrow stromal cells were
added to MLC or conA stimulation cultures at the
beginning of culture. Cells were labeled with 1 mCi/
well of 3H-thymidine for the final 16 hours of culture,
harvested onto glass fiber filters, and counted for
isotope incorporation.
To determine whether MSC-conditioned medium
(CM) was suppressive in MLC, CM was produced
from MSC lines (5-day culture), concentrated 10-
fold, and then added to allogeneic MLC at a 1:9 ratio
with freshmedium. To further assess whether cell con-
tact was required for MSC-mediated suppression of T
cell proliferation, irradiated MSCs were cocultured
with responder and irradiated stimulator PBMCs in
allogeneicMLC established on 24-well plates. In these
experiments, MSCs were either cultured in direct
contact with responders/stimulators or separated by
a 0.3-mm porous membrane on Transwell inserts
(Corning, Lowell, MA).Hematopoietic Cell Transplantation
Dogs
Litters of random-bred dogs were either raised
at the Fred Hutchinson Cancer Research Center
(FHCRC) or purchased from commercial Class A ven-
dors licensed by the US Department of Agriculture.
The dogs weighed 7.4-14.4 kg (median, 11.4 kg) and
were age 7-56 months (median, 9 months). All dogs
were enrolled in a veterinary preventive medicine
program that included routine antihelminthic agents
and a standard immunization series [24]. The study
was approved by the Institutional Animal Care and
Use Committee of FHCRC, which has been fully
accredited by the Association for Assessment and
Accreditation of Laboratory Animal Care. Littermate
donor–recipient pairs were selected on the basis of
complete family studies showing haploidentity for
highly polymorphic MHC-associated class I and II
microsatellite markers [25] and for DLA-DRB1 alleles
determined by direct sequencing [26].
Transplantation regimen
On day 0, donormarrowwas harvested and infused
intravenously into allogeneic recipients after a single
9.2-Gy dose of total body irradiation (TBI) delivered
at 7 cGy/min (Varian Clinac 4; Varian Medical
Systems, Palo Alto, CA). The median number of
nucleated marrow cells infused was 3.8  108 cells/kg
(range, 2.1-9.7  108 cells/kg) (Table 2). Recipients
were not given pharmacologic immunosuppression
for prevention of GVHD after transplantation.
MSC preparation and infusion
MSC lines DS1-3 and primary LTC-derived
MSCs were expanded to at least semiconfluencyex vivo using T250 culture flasks (Corning, Kenne-
bunk, MN). In an adaptation of previously
described methods for culture of human MSCs
[20,27], 10% heat-inactivated fetal calf serum was
substituted for pooled dog serum. MSCs were then
trypsinized, harvested, washed twice, and suspended
in 0.9%NaCl before infusion. The first MSC infusion
was given within 30 minutes after marrow graft infu-
sion. Three different MSC regimens were used
(Table 2):
(1) Seven recipients; DS1/DS2/DS3 in a 1:1:1 ratio;
total dose per infusion, 30  106/kg recipient
weight; given 3 days/week during the first week
post-HCT and on 2 days/week starting the second
week post-HCT.
(2) Five recipients;DS1/DS2/DS3 in a 1:1:1 ratio; total
dose per infusion, 15  106/kg recipient weight;
given 5 days/week.
(3) Three recipients; primary marrow stromal cells
pooled from 7 donors; total dose per infusion, 1 
106/kg recipient weight; given 3 days/week.Supportive care and study termination
Prophylaxis with oral antibiotics was given from
the day of TBI up to the end of the study. Broader an-
tibiotic coverage was administered when neutrophil
counts declined to\0.5  103/mL or fever developed.
Intravenous fluids were administered when dehydra-
tion occurred. Irradiated blood transfusionswere given
either when platelet count declined to\5 103/mL or
whenpetechiae and ecchymoses of the skin andmucous
membranes were observed. Clinical signs of acute
GVHD included diarrhea, skin erythema, and elevated
liver enzymes [28]. Dogs were euthanized if they were
in poor clinical condition, and complete necropsies
were performed, which allowed histopathological
distinction between GVHD and regimen-related
toxicities.
Statistical considerations
This study was designed to use the fewest dogs
necessary to have adequate power to detect differences
deemed clinically meaningful in comparison with our
historical results [29]. Based on 11 dogs given haploi-
dentical grafts and no pharmacologic immunosuppres-
sion after transplantation, the median survival was 15
days, and long-term survival (.100 days) did not
occur. It was predetermined that a group size of 7
dogs treated withMSCs provided 80% power to detect
an increase in median survival to 37 days, at a one-
sided .05 level of significance. Seven dogs also
provided 80% power to detect an increase in the
proportion of long-term survivors from 5% to 38%,
based on an exact binomial test at a 1-sided .05 level
of significance.
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Hematopoietic engraftment was assessed by in-
creases in granulocyte and platelet counts following
postirradiation nadirs, marrow histology from autopsy
specimens, documentation of donor-type hematopoie-
sis in peripheral blood and marrow by variable number
tandem repeat (VNTR) polymorphisms [30,31], and
clinical and histological evidence of GVHD.
In Vivo Distribution of 111In-Labeled DS1 Cells
DS1 cells were labeled in vitro with 111In (30 Bq/
cell) [32] before injection. Labeled cells were infused
into one recipient (G-943) immediately after adminis-
trationof8GyofTBI (delivered at7 cGy/minas a single
fraction). Single-photon emission computed tomogra-
phy images were obtained immediately after injection
and at 1, 2, 4, and 9 days after injection.
Detection of DS Cells In Vivo
MSC lines DS 1-3 were generated from one donor
dog (DLA-DRB1 3/6), which allowed their detection
in blood and tissue samples by VNTR-based polymor-
phism analysis [30,31]. For this purpose, DNA was
extracted from blood and tissue preparations. To
detect viable MSCs, blood or tissue obtained from
recipients at different time points after MSC infusion
were cultured in RPMI medium supplemented with
10% heat-inactivated dog serum, which allowed for
outgrowth of the immortalized cells. After 72 hours
of initial culture, nonadherent cells and debris were
rinsed off, and adherent cells were expanded for 7-14
days. Adherent layers were then trypsinized before
DNA extraction and chimerism analysis.RESULTS
Transcriptome Comparison of DS Lines
InDS lines 1-3, 130 genes with absolute expression
values .100 and adequate annotation to be classified
as ‘‘extracellular,’’ ‘‘chemokines/growth factors,’’ or
‘‘receptors’’ by Gene Ontology (GO slims) were con-
sidered for analysis. The clustering analysis of the rel-
ative expression of these 130 selected genes shows that
the 3 DS lines differ significantly from one another in
terms of their mRNA expression profiles (Figure 1).
The complete dataset showing transcriptomes for
these lines using the Affymetrix microarray platform
can be accessed at http://webapps.fhcrc.org/labs/
graf/grantdata.html.
Phenotypic Characterization of DS Lines and
Primary Marrow Stromal Cultures
Although primary marrow stromal cultures
(LTCs) showed variable expression of hematopoietic
lineage markers CD13, CD14, and CD45, thesemarkers were undetectable in DS lines 1-3 (Table 1).
In contrast, markers widely associated with cultured
human MSCs [33,34], including CD29 (integrin
b1-chain), CD73 (ecto-50-nucleotidase), and CD90
(Thy-1), were consistently expressed by DS 1-3 and
by most LTCs. Moreover, CD105 (endoglin) was
variably expressed by the different LTCs tested and
consistently expressed by all 3 DS lines. The 3 DS
lines did not express DLA class II or CD34.
Constitutive Production of Cytokines by DS
Cells and Primary Marrow Stromal Cells
The 3 DS lines were assayed for cytokine produc-
tion using the Lincoplex system (Millipore, Billerica,
MA). All 3 lines expressed low but consistent levels
of interleukin (IL)-4, IL-6, and IL-10 and did not
secrete detectable levels of granulocyte macrophage
colony-stimulating factor, interferon g, CXCL1,
IL-2, IL-15, IL-18, or tumor necrosis factor a (Table
2). DS1 and DS2 expressed high levels of IL-8,
whereas DS3 produced undetectable levels of IL-8.
DS1 and DS2 showed a 3-fold difference in monocyte
chemotactic protein 1 (MCP-1) production. Thus, in
terms of production of this limited panel of cytokines,
DS1 and DS2 were more similar, differing consider-
ably from DS3. The 12 cytokines assayed were also
represented on the Affymetrix microarrays; the consti-
tutive expression levels of two of these, IL-8 and
MCP-1, differed in DS3 compared with the other 2
lines. Thus, the transcriptome analysis lends weight
to the cytokine results and supports the concept of
functional heterogeneity among the generated clonal
MSC lines. Except for nondetectable levels of IL-8,
the cytokine profile of primary marrow stromal cells
(LTCs) was similar to that of DS1-3.
Suppression of Alloantigen-Driven T Cell
Proliferation by DS Cells
DS1,DS2, orDS3 cells were added at the initiation
of allogeneicMLCs at a 1:2DS cell/responder cell ratio
(Figure 2A).The results indicate that the 3DS lines had
variable inhibitory effects on T cell proliferation, with
DS3 resulting in.80% suppression ofMLCs andDS1
or DS2 resulting in 50%-70% suppression of MSCs.
MSC-CMwas then tested for its ability to suppress
T cell proliferation in allogeneic MLCs. For this
purpose, 5-day CM was produced and concentrated
10-fold before being added to MLCs at the initiation
of culture (final MSC-CM concentration, 1). As
shown in Figure 2B, MSC-CMwas only minimally ef-
fective in suppressing the allogeneic reaction, with
DS3-CM having the strongest impact (25% suppres-
sion). CM produced by coculture of the 3 DS lines was
equally ineffective in suppressing the proliferative
response as CM derived from culture of individual
DS lines (Figure 2B).
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Figure 2. Inhibition of T cell proliferation in canine allogeneic MLC by different marrow stromal cell lines (DS1-3) under contact and noncontact
conditions, and by stromal cell–conditioned medium. (A) Standard MLC was set up using PBMCs from unrelated DLA-mismatched dog pairs. Different
MSC lines, designated DS1-DS3, were irradiated and added at the initiation of MLC at a 2:1 responder/MSC ratio. All 3 DS lines tested had suppressive
effects on T cell proliferation. (B) Five-day DS cell CM was produced, concentrated 10-fold, and then added to allogeneic MLC in a 1:9-ratio with fresh
medium. The left panel shows results for CM from individual DS lines. The right panel shows results for CM produced by coculture of the 3 DS lines
(DS1/2/3 CM). (C) DS1 or DS3 cells were irradiated and cocultured with responder and irradiated stimulator PBMCs in allogeneic MLC established on
24-well plates. DS cells were either cultured in direct contact with responders/stimulators or separated by a 0.3-mm porous membrane on Transwell
inserts (1 insert). ‘‘Allo Control’’ refers to allogeneic MLCwithout addition of DS cells; ‘‘Auto Control’’ refers to MLCwithout addition of DS cells using
autologous responder and stimulator cells. One of 3 representative experiments is shown. Results for each experimental condition represent the mean6
standard error of the mean of 6 replicate wells. An asterisk indicates a statistically significant decrease in proliferative activity compared with Allo Con-
trols (P\.05, 2-tailed, Mann-Whitney U test).
Biol Blood Marrow Transplant 17:214-225, 2011 219MSCs and GVHDSuppression of T Cell Proliferation by DSCells Is
Contact-Independent
To determine whether the relative lack of suppres-
sion of T cell proliferation with MSC-CM was due to
the lack of cell contact, Transwell experiments were
conducted in which DS1 or DS3 cells were set up in
the upper chamber and separated by a porous 0.3-mm
membrane from the MLCs in the lower chamber
(Figure 2C). DS cells separated from responder and
stimulator cells were as effective in suppressing the
allogeneic MLCs as were DS cells added directly to
responder and stimulator cells.DS Cells Suppress Alloantigen- and
Mitogen-Stimulated T Cell Proliferation
in a Dose-Dependent Fashion
DS1, DS2, and DS3 cells, used singly or in combi-
nation (DS1/DS2/DS3 in a 1:1:1 ratio; DS-Mix), were
added to allogeneic MLCs (Figure 3A) or mitogen-
stimulated PBMCs (Figure 3B) in graded numbers.
The inhibition of T cell proliferation by DS cells was
cell dose–dependent, with DS3 cells and the DS-Mix
having the strongest suppressive effects. Allogeneic
MLC performed with titrated numbers of DS1/DS2/
DS3 (DS-Mix) in the presence of the prostaglandin
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Figure 3. Canine MSC lines DS1, DS2, and DS3 inhibit alloantigen- and
mitogen-induced T cell proliferation in a dose-dependent fashion. Differ-
ent numbers (3.12-50.0 103) of DS1, DS2, andDS3 cells, used singly or
in combination (DS-Mix), were irradiated and added to 105 canine
PBMCs that were stimulated with 105 irradiated allogeneic stimulator
PBMCs in allogeneic MLC or Con A. Shown are 1 of 5 representative
experiments using individual DS lines, and 1 of 2 representative experi-
ments using the DS-Mix. Results for each experimental condition repre-
sent the mean 6 standard error of the mean of 6 replicate wells. An
asterisk indicates a statistically significant decrease in proliferative
activity compared with controls cultured without DS cells (P \.05,
2-tailed, Mann-Whitney U test).
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cell–mediated suppression of T cell proliferation by
32%-56%, suggesting a partial role of prostaglandin
E in DS cell–mediated suppression of T cell
proliferation.Figure 4. In vivo distribution of 111In-labeled DS1 cells in a beagle dog (G-943
immediately after 8 Gy TBI (delivered at 7 cGy/min as a single fraction). The d
cipient weight. Single-photon emission computed tomography images were obt
Shown are anterior views in craniocaudal (top to bottom) orientation.In Vivo Distribution of 111In-Labeled MSCs
To better understand the in vivo distribution of
immortalized marrow stromal cells, DS1 cells were la-
beled with 111In and injected intravenously into a bea-
gle dog. The distribution of the label was then
monitored over time using a gamma camera. Based
on the assumption that the detected radioactivity was
associated with DS1 cells, we found that DS1 cells ac-
cumulated in the lung immediately after infusion (day
0), but then left the lung within 24 hours and preferen-
tially redistributed to liver and spleen; weaker signals
were detectable in bone marrow and gut (Figure 4).
Residual label in liver and spleen could be detected
as long as 9 days after infusion.
Infusions of DS Cells or Primary Marrow
Stromal Cells after DLA-Haploidentical Marrow
Transplantation DoNot PreventGVHDorGraft
Rejection
The dogs given DLA-haploidentical marrow
grafts without pharmacologic postgrafting immuno-
suppression (n 5 11) had a median survival of 15
days (range, 13-25 days) (Table 3) [29]. Seven recipi-
ents (64%) rejected their grafts, and 4 (36%) engrafted
with ensuing lethal GVHD. Based on this historical
experience, we examined whether postgrafting MSC
infusions, by virtue of their putative immunosuppres-
sive effects, might increase rates of engraftment and
mitigate GVHD after engraftment. Thus, MSCs
were infused after transplant according to the 3 regi-
mens detailed in Materials and Methods (Table 3).
Three dogs (dogs 13-15) were given primary LTC-
derived MSCs that had been pooled from 7 different
marrow donors. Even though the doses of primary
MSCs were substantially lower than those of DS1-3
cells administered (3  106/kg/week vs 60-90  106/
kg/week), they were consistent with MSC doses given
in previous clinical GVHD treatment studies [17,18].
Compared with historical controls that underwent
transplantation in accordance with similar supportive
care standards, postgrafting MSC infusions did not). DS1 cells were labeled with 111In in vitro and then injected into the dog
ose of labeled and subsequently injected DS1 cells was 28  106/kg re-
ained immediately after injection and at 1, 2, 4, and 9 days after injection.
Table 3. Graft Composition and Outcome of DLA-Haploidentical Marrow HCTWith and Without MSC Infusion Following 9.2 y TBI
Dog
Donor
ID
Recipient
ID
Recipient
Weight, kg
DLA-DRB1 Bone Marrow Cell Dose MSC Treatment
Rej tion
Clinical and Histological GVHD
Survival,
Days
Hematopoietic
Chimerism
at NecropsyDonor Recipient MSC
TNC
(108/kg)
CD34
(106/kg)
CD3
(107/kg)
MSC
Type
Doses/
Week
Single Dose
(106 cells/kg) Skin Liver Gut
1 G-897 H-003 13.2 3/6 3/9 3/6 3 0.9 1.02 DS1/2/3‡ 2-3 30 o Yes Yes 17 Donor
2 G-993 G-988 12.6 6/9 9/17 3/6 2.1 0.42 1.28 DS1/2/3 2-3 30 o Yes Yes Yes 18 Donor
3 G-896 H-006 14.3 9/20 6/20 3/6 3.8 2.28 1.44 DS1/2/3 2-3 30 s 18 Host
4 H-030 H-029 13.4 3/22 20/22 3/6 5.5 1.1 2.53 DS1/2/3 2-3 30 o Yes Yes 18 Donor
5 H-098 H-097 9.1 2/15 2/17 3/6 3.6 0.36 1.22 DS1/2/3 2-3 30 s 18 Host
6 H-095 H-096 10.6 2/3 2/15 3/6 3.8 1.52 2.55 DS1/2/3 2-3 30 s 16 Host
7 H-092 H-093 7.4 3/9 9/15 3/6 7.1 4.26 4.47 DS1/2/3 2-3 30 E 3 NE
8 H-101 H-100 11.5 9/17 9/15 3/6 6.8 5.44 3.67 DS1/2/3 5 15 s 18 Host
9 H-139 H-130 7.8 15/22 19/22 3/6 5.0 6.5 2.8 DS1/2/3 5 15 s >280† Host
10 H-053 H-048 9.2 20/22 3/22 3/6 9.7 5 0.97 DS1/2/3 5 15 o Yes 14 Donor
11 G-550 H-098 10.4 2/9 2/15 3/6 8.6 19.8 2.84 DS1/2/3 5 15 o Yes 13 Donor
12 G-550 H-099 14.5 2/9 2/15 3/6 2.3 1.16 2.07 DS1/2/3 5 15 o Yes Yes Yes 18 Donor
13 H-178 H-176 11.4 14/15 6/14 * 3.7 2.22 2.52 Primary§ 3 1 o Yes Yes 14 Donor
14 H-180 H-175 9.5 6/9 6/14 * 3.5 2.8 3.74 Primary 3 1 s 25 Host
15 H-180 H-179 11.5 6/9 6/14 * 5 5 4.9 Primary 3 1 s 24 Host
Median 11.4 3.8 2.3 2.5 18
Without MSC infusions: historical data [29]
Dogs Studied Recipient
Weight, kg
Bone Marrow Cell
Dose, Median (Range)
R ction,
(%)
GVHD,
n (%)
Median
Survival,
Days
(Range)TNC (108/kg) CD34 (106/kg) CD3 (107/kg)
11 10.1 (6.5-15) 3.1 (1.0-4.4) 2.8 (2.0-4.9) 1.3 (1.2-2.9) 7 4) 4 (36) 15 (13-25)
TNC indicates total nucleated cells; NE, not evaluable.
*The DLA-DRB1 types of the different primary MSC donors were as follows: 1/6, 3/9, 3/15, 6/9, 9/17, 9/27, and 15/22.
†Dog rejected and, after a long duration of profound pancytopenia, survived with autologous hematopoietic recovery.
‡DS cell lines 1-3 were always infused at a 1:1:1 ratio.
§Primary MSC products in all 3 treated dogs were generated from 7 different donors as described in Materials and Methods, pooled, and infused a approximately equal ratios.
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Figure 5. Survival of dogs prepared with 9.2 Gy TBI followed by bone
marrow transplantation from a DLA-haploidentical donor. No pharma-
cologic immunosuppression was administered after transplantation.
MSC: MSC infusions were given after transplantation (n5 15). Control:
No MSC infusions were given after transplantation (n 5 11) [29]. One
dog given MSCs (H-130; see Table 2) rejected the graft and, after pro-
longed myelosuppression, survived with autologous hematopoiesis (ab-
solute neutrophil and platelet counts exceeding 0.5  103/mL and 20 
103/mL on days 40 and 56 after transplantation, respectively). Survival did
not differ significantly between the 2 groups (P 5 .18, log-rank test).
222 Biol Blood Marrow Transplant 17:214-225, 2011M. Mielcarek et al.significantly improve survival (15 days [range, 13-25
days] vs 18 days [range, 3$280 days]), rates of rejection
(64% vs 50%) and rates of GVHD (36% vs 50%) (P5
.69, Fisher’s exact test) (Table 3). One dog (H-093)
died on day 3 posttransplantation from acute gastroin-
testinal toxicity related to the conditioning regimen
and thus was not evaluable for rejection or GVHD.
One dog treated with DS cell infusions (H-130) re-
jected the marrow graft and survived with autologous
hematopoietic reconstitution. Even though the num-
bers were too small for meaningful intergroup com-
parisons, no MSC regimen appeared to be effective
in preventing the two major endpoints of this clinical
study, rejection and GVHD. Whereas 3 of 12 recipi-
ents of DS cell infusions received DLA-
haploidentical MSCs (Table 3), 9 recipients received
fully mismatched MSCs. There was no indication
that DLA compatibility between the MSC product
and the recipient had an effect on rates of rejection
and GVHD. The Kaplan-Meier survival curves for
MSC-treated recipients and historical controls are
shown in Figure 5.Detection of MSCs in Blood and Tissues
Of the 12 recipients given combined infusions of
DS1-3 cells, 7 recipients were analyzed for in vivo de-
tection of MSCs after infusion (Table 4). Immediately
after intravenous infusion, DS cells were detected in
the blood by PCR in only 1 of 7 recipients evaluated.
At 24, 48, and 72 hours after infusion, PCR products
specific for DS cells could be detected in 3 of 6, 1 of
4, and 1 of 4 recipients evaluated, respectively. How-
ever, after 7-14 days, DS signals could be detected inthe blood of all 7 recipients. Tissue samples obtained
from 6 recipients at necropsy were also subjected to
PCR analysis (Table 4). Without previous ex vivo ex-
pansion of stromal elements, DS cell–specific signals
were not detected in any of the samples tested; how-
ever, after ex vivo expansion, DS cell–specific signals
were found in the bone marrow, lung, and spleen in
2 of 6 dogs evaluated. None of the dogs infused with
DS cells showed clinical or histopathological evidence
of tumor formation even though cells were immortal-
ized and clonal in nature.DISCUSSION
By administering third-party bone marrow–
derived MSCs in large numbers and at high frequency
after DLA-haploidentical bone marrow transplanta-
tion, we hoped to prevent or at least mitigate acute
GVHD. In addition, by giving bone marrow that was
not supplemented with a T cell–rich buffy coat and
by not using pharmacologic immunosuppression after
transplantation, this well-established preclinical model
allowed us to use graft rejection as an additional read-
out for MSC-mediated immunosuppression in vivo.
The majority of recipients were given a combina-
tion of 3 different marrow stromal cell lines (derived
from one donor dog) that shared phenotypical features
associated with human MSCs [33,34] and had the
ability to suppress allogeneic T cell proliferation in
vitro. In fact, their T cell suppressive potential in
vitro was similar to or greater than that observed
with primary LTC-derived MSCs [12]. Analogous to
what has been reported previously with primary
MSCs in vitro, T cell suppression by DS cells was un-
restricted by antigens encoded by the MHC and was
contact-independent. Even though DS cells sup-
pressed the T cell proliferative response to alloantigen
in a contact-independent manner, DS cell–condi-
tioned medium was only minimally suppressive. This
finding suggests that soluble factors released during
the allogeneic immune response might induce MSCs
to release a soluble mediator that interferes with T
cell function. Several soluble factors (including trans-
forming growth factor b, hepatocyte growth factor,
and prostaglandin E2, among others) have been pro-
posed to mediate the suppressive effects of human
MSCs [35-37] and canine MSCs [12] in vitro. Our
findings also suggest that prostaglandins are involved
in DS-mediated immunosuppression in vitro.
Although all 3 DS lines used in our study sup-
pressed alloantigen- and mitogen-induced T cell pro-
liferation in vitro, they differed from one another with
respect to their immune phenotype, mRNA expression
profile, and repertoire of secreted cytokines. The use
ofMSC products composed of 3 phenotypically differ-
ent MSC lines isolated from the same LTC was done
Table 4. Detection of Third-Party DS Cells in Blood and Tissues
Dog
Recipient
ID
Blood or Tissue
Enriched for
MSC before
Detection by
VNTR
MSC Detection
NecropsyIn Blood, Hours after Infusion In Tissue at Necropsy
0 24 48 72 BM Lung Liver Spleen LN
Day after
HCT BM Cellularity, % Chimerism
1 H-003 No Yes No No No No No No 17 50 Donor
Yes Yes Yes Yes Yes ng No No
2 G-988 No No No No No No No 18 50 Donor
Yes Yes No ng ng ng No
3 H-006 No No No No No No No No No 18 5 Host
Yes Yes Yes Yes Yes Yes ng Y es ng
4 H-029 No No No No No No No No No 18 80 Donor
Yes Yes Yes Yes No No No No No
5 H-097 No No No No No No No No No No 18 0 Host
Yes Yes No No No ng ng ng ng ng
6 H-096 No No No No No No No No No No 16 0 Host
Yes Yes No No No No No No No No
7 H-130 No No No No No NA NA NA NA NA Alive NA Host
Yes Yes No No No
BM indicates bone marrow; LN, lymph node; ng, no growth; NA, not applicable.
MSC lines DS1-3 were generated from one donor dog, which allowed their detection in blood and tissue samples by VNTR-based polymorphism anal-
ysis. For this purpose, DNA was extracted from unmodified or MSC-enriched white blood cell (WBC) and tissue preparations. To enrich for viable
MSCs, WBCs obtained from recipients at different time points after MSC infusion, or minced tissue samples obtained at necropsy were cultured in
RPMI medium supplemented with 10% heat-inactivated dog serum on 12-well plates. After 72 hours of initial culture, nonadherent cells and debris
were rinsed off, and adherent cells were expanded for 7-14 days. Adherent layers were then trypsinized before DNA extraction and subjected to chi-
merism analysis as described in Materials and Methods. In cases where DS cells were detectable by chimerism analysis after ex vivo expansion of ad-
herent stromal cells (‘‘Yes’’), DS cell–specific signals consistently exceeded 80%.
Biol Blood Marrow Transplant 17:214-225, 2011 223MSCs and GVHDto provide an unlimited amount of a consistent cell
product for experimental use that would mimic the
heterogeneous composition of primary MSCs.
Our results in this established canine model show
that compared with historical controls (n 5 11) given
9.2-Gy TBI and DLA-haploidentical marrow grafts
without MSC infusions after transplantation, recipi-
ents ofMSCs (n5 15) experienced similar rates ofmar-
row graft rejection. Moreover, all 7 MSC recipients
that had donor marrow engraftment (50%) developed
vicious and rapidly fatal acute GVHD, identical to
the experience with historical controls. As a result, sur-
vival curves for MSC-treated dogs and controls were
virtually identical. Even though ameaningful subgroup
analysis was limited by small numbers, no MSC regi-
men appeared to be effective in preventing the twoma-
jor endpoints of this preclinical study, rejection and
GVHD. Primary MSCs also were ineffective in pre-
venting or treating GVHD and rejection. This finding
is consistent with a recent study by Lee et al. [12] show-
ing that donor-derived primary MSCs did not prevent
marrow graft rejection after DLA-identical HCT.
There was also no indication in our study that the de-
gree of DLA compatibility between MSC products
and recipients affected the rates of rejection and
GVHD. Finally, it is important to emphasize that be-
cause no therapeutic benefits associated with MSC in-
fusions were found, a significant bias related to the use
of historical controls appears to be unlikely.
Additional analysis showed that 111In-labeled
DS1 cells accumulated in the lungs immediately afterintravenous infusion and within 24 hours redistributed
to the liver, spleen, and bonemarrow. Thus, the in vivo
distribution of DS1 cells was similar to that described
for primary marrow–derived MSCs studied in other
animal models [38,39]. In addition, the in vivo
distribution of DS1 cells in this irradiated dog was
not different from that in 2 nonirradiated dogs
studied previously (data not shown). A limitation of
this analysis, however, is the fact that the distribution
of the 111In label might not have been indicative of
viable cells because detection of 111In signals in
parenchymal organs could be due to retention of free
111In label by macrophages. Thus, we sought to
detect viable DS cells in various organs at the time of
necropsy. For this purpose, stromal cells were
expanded from organ samples before subjecting them
to DS cell–specific PCR analyses. Even though the
expansion of stromal cells from organ samples was
not uniformly successful, DS cells could be expanded
from the lungs, spleen, and marrow of 2 dogs. These
limited data suggest that after high-dose irradiation
of recipients, allogeneic DLA-mismatched DS cells
could migrate to and survive in parenchymal organs
for several days after infusion. Given that detection
of DS cells was virtually impossible in organ samples
and PBMCs without ex vivo expansion of stromal cells,
the relative frequency of circulating and tissue-based
DS cells after infusion appeared to be low.
In conclusion, our results obtained in the clinically
relevant canine model of allogeneic HCT indicate that
marrow-derived clonal and primary MSCs, although
224 Biol Blood Marrow Transplant 17:214-225, 2011M. Mielcarek et al.strongly immunosuppressive in vitro, have no identifi-
able immunosuppressive activity in vivo. MSCs were
administered frequently and in doses typically undeliv-
erable in clinical transplantation; however, the MSC
regimens used in this study failed to prevent graft re-
jection and GVHD, the two major immunologic bar-
riers of allogeneic transplantation. It is possible that
the DS lines used in our study were not representative
of primary MSCs used in and associated with success-
ful treatment of GVHD in clinical studies [17]. How-
ever, outcomes with primary MSCs were not different
from those withDS cells. Due to the rigorous nature of
our model, it is also possible that the addition ofMSCs
to a regimen of pharmacologic immunosuppression
might have been more successful. At the very least,
these data emphasize a disconnect between in vitro
and in vivo data. Given that the medical literature
tends to favor positive study results, our study should
serve as a counterpoint emphasizing that the in vivo
immunosuppressive effects of MSC have not yet
been defined unequivocally.ACKNOWLEDGMENTS
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